The Administrators of the Tulane Educational Fund

Autoimmune Technologies, LLC

United States of America, As Represented by the Secretary of Agriculture

Xavier University of Louisiana

The Administration of the Tulane Educational Fund

Bruce Alan Bunnell

Robert F Garry

Russell B Wilson

Luis Manuel Branco

Samuel E Hopkins

John D Clements

Guangdi Wang

Matthew E Burow

Stephen M Boue

Shilong Zheng

Quan Jiang

Elizabeth Bray Norton

Stephen E Braun

Luis M Branco

Debasis Mondal

Nicholas C Pashos

Suzanne L Tomchuck

Narae Lee

Amy Strong

A composition of matter and method of treating HIV with mesenchymal stem cells (MSC) is disclosed. Specifically, MSCs are transduced with vectors incorporating an anti-viral fusion inhibitor, such as a C46-derived peptide or neutralizing antibody. The transduced MSCs are capable of expression the inhibitor and preventing HIV virus-cell fusion.

Expression of HIV inhibitors by mesenchymal stem cells

Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN&#x3b1;, IFN&#x3b2;, or IFN&#x3c9;), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Immunoprotective primary mesenchymal stem cells and methods

Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.

Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells

The present disclosure relates to surgical grafts for replacing nipples and areolas lost to disease or trauma with surgical grafts of decellularized donor nipples and areolas and to placing and recellularizing such grafts. The disclosure further provides methods for decellularizing epidermis. The decellularized epidermis can be used as a protective cover for skin wounds.

Surgical grafts for replacing the nipple and areola or damaged epidermis

Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.

Primary mesenchymal stem cells as a vaccine platform

Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN&#x3b1;, IFN&#x3b2;, or IFN&#x3c9;), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Growing community of inventors

Mandeville, LA, United States of America

Bruce Alan Bunnell